Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment

Lorenzo G. Mantovani, M. S. Monzini, P. M. Mannucci, L. Scalone, M. Villa, A. Gringeri, Giovanni Barillari, Francesco Baudo, Atto Billio, Luisa Bizzoni, Elio Boeri, Biagio Caputo, Giancarlo Castaman, Laura Contino, Grazia Delios, Antonio Coppola, Alfredo Dragani, Giulio Feola, Daniela Bertuzzo, Marco D'IncàElena Santagostino, PierGiorgio Iannaccaro, Alfonso Iorio, Giacomo Mancuso, Massimo Morfini, Roberto Musso, Gavino Piseddu, Angiola Rocino, Giuseppina Rodorigo, Gina Rossetti, Francesco Antonio Scaraggi, Mario Schiavoni, PierCarla Schinco, Giuseppe Tagariello, Annarita Tagliaferri, Roberto Targhetta, Vincenzo Trapani Lombardo, Ezio Zanon

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The provision of health care to patients with haemophilia through replacement of the deficient coagulation factor is the result of a complex interaction between patients, physicians and policy makers, each carrying their individual sets of preferences. Preferences of patients, physicians and pharmacists towards perceived viral safety, risk of inhibitor development, infusion frequency during prophylaxis, pharmaceutical dosage form, distribution modes and price were evaluated by conjoint analysis, using a discrete choice experiment. Overall 178 patients', 69 physicians and 58 pharmacists completed the study. Patients, physicians and pharmacists displayed preferences: (i) similar in direction and strength for risk of inhibitors and frequency of prophylaxis, (ii) similar in direction, but not in strength for perceived viral safety and price, with patients showing lower strength compared with physicians and pharmacists, and (iii) dissimilar in direction and/or strength for: (i) dosage form, which tested important only for pharmacists and (ii) distribution mode, which tested important for patients and physicians only. Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care.

Original languageEnglish
Pages (from-to)589-597
Number of pages9
JournalHaemophilia
Volume11
Issue number6
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Hemophilia A
Pharmacists
Physicians
Dosage Forms
Therapeutics
Safety
Blood Coagulation Factors
Patient Preference
Administrative Personnel
Delivery of Health Care
Pharmaceutical Preparations
Direction compound

Keywords

  • Coagulation factor concentrates
  • Conjoint analysis
  • Discrete choice experiment
  • Haemophilia
  • Inhibitor
  • Preferences

ASJC Scopus subject areas

  • Hematology

Cite this

Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia : A discrete choice experiment. / Mantovani, Lorenzo G.; Monzini, M. S.; Mannucci, P. M.; Scalone, L.; Villa, M.; Gringeri, A.; Barillari, Giovanni; Baudo, Francesco; Billio, Atto; Bizzoni, Luisa; Boeri, Elio; Caputo, Biagio; Castaman, Giancarlo; Contino, Laura; Delios, Grazia; Coppola, Antonio; Dragani, Alfredo; Feola, Giulio; Bertuzzo, Daniela; D'Incà, Marco; Santagostino, Elena; Iannaccaro, PierGiorgio; Iorio, Alfonso; Mancuso, Giacomo; Morfini, Massimo; Musso, Roberto; Piseddu, Gavino; Rocino, Angiola; Rodorigo, Giuseppina; Rossetti, Gina; Scaraggi, Francesco Antonio; Schiavoni, Mario; Schinco, PierCarla; Tagariello, Giuseppe; Tagliaferri, Annarita; Targhetta, Roberto; Lombardo, Vincenzo Trapani; Zanon, Ezio.

In: Haemophilia, Vol. 11, No. 6, 11.2005, p. 589-597.

Research output: Contribution to journalArticle

Mantovani, LG, Monzini, MS, Mannucci, PM, Scalone, L, Villa, M, Gringeri, A, Barillari, G, Baudo, F, Billio, A, Bizzoni, L, Boeri, E, Caputo, B, Castaman, G, Contino, L, Delios, G, Coppola, A, Dragani, A, Feola, G, Bertuzzo, D, D'Incà, M, Santagostino, E, Iannaccaro, P, Iorio, A, Mancuso, G, Morfini, M, Musso, R, Piseddu, G, Rocino, A, Rodorigo, G, Rossetti, G, Scaraggi, FA, Schiavoni, M, Schinco, P, Tagariello, G, Tagliaferri, A, Targhetta, R, Lombardo, VT & Zanon, E 2005, 'Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment', Haemophilia, vol. 11, no. 6, pp. 589-597. https://doi.org/10.1111/j.1365-2516.2005.01159.x
Mantovani, Lorenzo G. ; Monzini, M. S. ; Mannucci, P. M. ; Scalone, L. ; Villa, M. ; Gringeri, A. ; Barillari, Giovanni ; Baudo, Francesco ; Billio, Atto ; Bizzoni, Luisa ; Boeri, Elio ; Caputo, Biagio ; Castaman, Giancarlo ; Contino, Laura ; Delios, Grazia ; Coppola, Antonio ; Dragani, Alfredo ; Feola, Giulio ; Bertuzzo, Daniela ; D'Incà, Marco ; Santagostino, Elena ; Iannaccaro, PierGiorgio ; Iorio, Alfonso ; Mancuso, Giacomo ; Morfini, Massimo ; Musso, Roberto ; Piseddu, Gavino ; Rocino, Angiola ; Rodorigo, Giuseppina ; Rossetti, Gina ; Scaraggi, Francesco Antonio ; Schiavoni, Mario ; Schinco, PierCarla ; Tagariello, Giuseppe ; Tagliaferri, Annarita ; Targhetta, Roberto ; Lombardo, Vincenzo Trapani ; Zanon, Ezio. / Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia : A discrete choice experiment. In: Haemophilia. 2005 ; Vol. 11, No. 6. pp. 589-597.
@article{022cf57fe1304ead96730143cf33c2e7,
title = "Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment",
abstract = "The provision of health care to patients with haemophilia through replacement of the deficient coagulation factor is the result of a complex interaction between patients, physicians and policy makers, each carrying their individual sets of preferences. Preferences of patients, physicians and pharmacists towards perceived viral safety, risk of inhibitor development, infusion frequency during prophylaxis, pharmaceutical dosage form, distribution modes and price were evaluated by conjoint analysis, using a discrete choice experiment. Overall 178 patients', 69 physicians and 58 pharmacists completed the study. Patients, physicians and pharmacists displayed preferences: (i) similar in direction and strength for risk of inhibitors and frequency of prophylaxis, (ii) similar in direction, but not in strength for perceived viral safety and price, with patients showing lower strength compared with physicians and pharmacists, and (iii) dissimilar in direction and/or strength for: (i) dosage form, which tested important only for pharmacists and (ii) distribution mode, which tested important for patients and physicians only. Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care.",
keywords = "Coagulation factor concentrates, Conjoint analysis, Discrete choice experiment, Haemophilia, Inhibitor, Preferences",
author = "Mantovani, {Lorenzo G.} and Monzini, {M. S.} and Mannucci, {P. M.} and L. Scalone and M. Villa and A. Gringeri and Giovanni Barillari and Francesco Baudo and Atto Billio and Luisa Bizzoni and Elio Boeri and Biagio Caputo and Giancarlo Castaman and Laura Contino and Grazia Delios and Antonio Coppola and Alfredo Dragani and Giulio Feola and Daniela Bertuzzo and Marco D'Inc{\`a} and Elena Santagostino and PierGiorgio Iannaccaro and Alfonso Iorio and Giacomo Mancuso and Massimo Morfini and Roberto Musso and Gavino Piseddu and Angiola Rocino and Giuseppina Rodorigo and Gina Rossetti and Scaraggi, {Francesco Antonio} and Mario Schiavoni and PierCarla Schinco and Giuseppe Tagariello and Annarita Tagliaferri and Roberto Targhetta and Lombardo, {Vincenzo Trapani} and Ezio Zanon",
year = "2005",
month = "11",
doi = "10.1111/j.1365-2516.2005.01159.x",
language = "English",
volume = "11",
pages = "589--597",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia

T2 - A discrete choice experiment

AU - Mantovani, Lorenzo G.

AU - Monzini, M. S.

AU - Mannucci, P. M.

AU - Scalone, L.

AU - Villa, M.

AU - Gringeri, A.

AU - Barillari, Giovanni

AU - Baudo, Francesco

AU - Billio, Atto

AU - Bizzoni, Luisa

AU - Boeri, Elio

AU - Caputo, Biagio

AU - Castaman, Giancarlo

AU - Contino, Laura

AU - Delios, Grazia

AU - Coppola, Antonio

AU - Dragani, Alfredo

AU - Feola, Giulio

AU - Bertuzzo, Daniela

AU - D'Incà, Marco

AU - Santagostino, Elena

AU - Iannaccaro, PierGiorgio

AU - Iorio, Alfonso

AU - Mancuso, Giacomo

AU - Morfini, Massimo

AU - Musso, Roberto

AU - Piseddu, Gavino

AU - Rocino, Angiola

AU - Rodorigo, Giuseppina

AU - Rossetti, Gina

AU - Scaraggi, Francesco Antonio

AU - Schiavoni, Mario

AU - Schinco, PierCarla

AU - Tagariello, Giuseppe

AU - Tagliaferri, Annarita

AU - Targhetta, Roberto

AU - Lombardo, Vincenzo Trapani

AU - Zanon, Ezio

PY - 2005/11

Y1 - 2005/11

N2 - The provision of health care to patients with haemophilia through replacement of the deficient coagulation factor is the result of a complex interaction between patients, physicians and policy makers, each carrying their individual sets of preferences. Preferences of patients, physicians and pharmacists towards perceived viral safety, risk of inhibitor development, infusion frequency during prophylaxis, pharmaceutical dosage form, distribution modes and price were evaluated by conjoint analysis, using a discrete choice experiment. Overall 178 patients', 69 physicians and 58 pharmacists completed the study. Patients, physicians and pharmacists displayed preferences: (i) similar in direction and strength for risk of inhibitors and frequency of prophylaxis, (ii) similar in direction, but not in strength for perceived viral safety and price, with patients showing lower strength compared with physicians and pharmacists, and (iii) dissimilar in direction and/or strength for: (i) dosage form, which tested important only for pharmacists and (ii) distribution mode, which tested important for patients and physicians only. Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care.

AB - The provision of health care to patients with haemophilia through replacement of the deficient coagulation factor is the result of a complex interaction between patients, physicians and policy makers, each carrying their individual sets of preferences. Preferences of patients, physicians and pharmacists towards perceived viral safety, risk of inhibitor development, infusion frequency during prophylaxis, pharmaceutical dosage form, distribution modes and price were evaluated by conjoint analysis, using a discrete choice experiment. Overall 178 patients', 69 physicians and 58 pharmacists completed the study. Patients, physicians and pharmacists displayed preferences: (i) similar in direction and strength for risk of inhibitors and frequency of prophylaxis, (ii) similar in direction, but not in strength for perceived viral safety and price, with patients showing lower strength compared with physicians and pharmacists, and (iii) dissimilar in direction and/or strength for: (i) dosage form, which tested important only for pharmacists and (ii) distribution mode, which tested important for patients and physicians only. Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care.

KW - Coagulation factor concentrates

KW - Conjoint analysis

KW - Discrete choice experiment

KW - Haemophilia

KW - Inhibitor

KW - Preferences

UR - http://www.scopus.com/inward/record.url?scp=27744504877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744504877&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2005.01159.x

DO - 10.1111/j.1365-2516.2005.01159.x

M3 - Article

C2 - 16236108

AN - SCOPUS:27744504877

VL - 11

SP - 589

EP - 597

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -